Connect Biopharma Holdings Limited (CNTB) stock surged +2.75%, trading at $1.12 on NASDAQ, up from the previous close of $1.09. The stock opened at $1.12, fluctuating between $1.04 and $1.14 in the recent session.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Employees | 81 |
Beta | -0.31 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock price is $1.12 in the last trading session. During the trading session, CNTB stock reached the peak price of $1.14 while $1.04 was the lowest point it dropped to. The percentage change in CNTB stock occurred in the recent session was 2.75% while the dollar amount for the price change in CNTB stock was $0.03.
The NASDAQ listed CNTB is part of Biotechnology industry that operates in the broader Healthcare sector. Connect Biopharma Holdings Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Steven Chan
Chief Financial Officer
Dr. Chin Lee M.D., M.P.H.
Chief Medical Officer
Mr. Jiang Bian J.D.
Gen. Counsel & Chief Compliance Officer
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, Pres & Chairman of Directors
Dr. Raul Collazo Ph.D.
Vice President & Global Head of Medical Affairs
Dr. Lei Sun Ph.D.
Vice President of Biologics & Head of CMC
Dr. Malinda V. Longphre Ph.D.
Vice President & Head of US Clinical Operations
Dr. Zheng Wei Ph.D.
Co-Founder, Chief Executive Officer & Director
CNTB's closing price is 65.19% higher than its 52-week low of $0.68 where as its distance from 52-week high of $2.66 is -57.9%.
Number of CNTB employees currently stands at 81.
Official Website of CNTB is: https://www.connectbiopharm.com
CNTB could be contacted at phone 865 125 3577866 and can also be accessed through its website. CNTB operates from East R&D Building, Taicang, 215400, China.
CNTB stock volume for the day was 33.72K shares. The average number of CNTB shares traded daily for last 3 months was 26.35K.
The market value of CNTB currently stands at $61.88M with its latest stock price at $1.12 and 55.25M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com